Pros and cons of weight-loss jabs
Weight-loss jabs, such as Ozempic, Wegovy and Mounjaro, have quickly earned a glowing global reputation for shifting the ...
GlobalData on MSN10h
Novo Nordisk plans new study for CagriSema, targets 2026 submission
CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...
New Atlas22h
Ozempic is suspected in more cases of sudden vision loss
Scientists remain puzzled as to why some individuals taking popular weight loss and diabetes medications such as Ozempic and ...
Psychology Today13h
Ozempic for the Rich, Body Positivity for the Poor
Moreover, the stigma surrounding obesity disproportionately affects lower-income individuals, who are often blamed for their ...
Ozempic Could Get Way Too Expensive Under Trump—Here's What You Can Do
While it may seem strange that politics could impact the price of popular weight loss drugs, it is a definite possibility.
Amgen Q4 Earnings: Good Quarter, Ok Guidance, But MariTide Concerns Me (Rating Downgrade)
Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.
Hosted on MSN13h
Ozempic Now FDA-Approved for Kidney Disease-Here's What to Know
GLP-1 medications are renowned for their ability to treat type 2 diabetes and aid weight loss. Now, there's a new benefit to ...
Hims & Hers Health down as Super Bowl ad draws controversy
An advocacy group that includes the main pharmaceutical lobbying organization, PhRMA, as a member is complaining that a commercial Hims & Hers Health (NYSE:HIMS) is slated to run during the Super Bowl ...